Skye Bioscience, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share of Common Stock

Net Loss Per Share of Common Stock

12 Months Ended

Dec. 31, 2018

7. Net Loss Per Share of Common Stock

The following table is a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations for the years ended December 31, 2018 and 2017:

	Year Ended December 31,
	2018			2017
Net loss	$	(19,194,236	)	$	(4,138,298	)
Weighted average common shares outstanding – basic and diluted		121,154,334			27,906,090
Net loss per share – basic and diluted	$	(0.16	)	$	(0.11	)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:

	Year Ended December 31,
	2018		2017
Stock options		3,600,073		1,130,000
Unvested restricted stock		1,543,501		1,050,000
Common shares underlying convertible debt		5,000,000		4,000,000
Common shares underlying convertible preferred stock		-		50,335,500
Warrants		53,130,750		11,649,500